Chiesi to acquire KalVista Pharmaceuticals for $1.9 billion in cash deal
read at Endpoints ↗DealPositive
Italian pharma Chiesi announced it will purchase commercial biotech KalVista Pharmaceuticals.
The transaction is valued at about $1.9 billion, with Chiesi paying $27 per share in cash.
The acquisition adds KalVista’s approved drug to Chiesi’s portfolio and reflects the ongoing spring acquisition activity in the industry.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Chiesi signs $1.9B deal to acquire KalVista and its approved drug”
read at Endpoints ↗82 words · retrieved Apr 29
comments(0)
5-min edit window · permanent after that